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Abstract
Choroideremia (CHM) is a slowly progressive X-linked retinal degeneration that results ultimately in total
blindness due to loss of photoreceptors, retinal pigment epithelium, and choroid. CHM, the gene implicated
in choroideremia, encodes Rab escort protein-1 (REP-1), which is involved in the post-translational
activation via prenylation of Rab proteins. We evaluated AAV8.CBA.hCHM, a human CHM encoding
recombinant adeno-associated virus serotype 8 (rAAV8) vector, which targets retinal cells efficiently, for
therapeutic effect and safety in vitro and in vivo in a murine model of CHM. In vitro studies assayed the
ability of the vector to produce functional REP-1 protein in established cell lines and in CHM patient derived
primary fibroblasts. Assays included Western blots, immunofluorescent labeling, and a REP-1 functional assay
which measured the ability of exogenous REP-1 to prenylate Rab proteins. The in vivo work used unilateral
subretinal delivery of AAV8.hCHM to treat a murine model of CHM, with the effects of treatment evaluated
with pupillometry, ophthalmoscopy, histology, and immunofluorescence analysis. The contralateral eye was
treated with an AAV8.EGFP control. The results of the in vitro analysis demonstrated that the
AAV8.CBA.hCHM vector was capable of inducing robust expression of REP-1 protein in a dose-responsive
fashion in cultured cells, with the prenylation assay indicating that the exogenous REP-1 protein produced
was capable of assisting in the activation of Rab proteins. This functional assay was also applied to CHM
patient fibroblasts transduced with an AAV serotype 2 version of the vector and demonstrated that exogenous
REP-1 produced in these cells was functional. The in vivo subretinal treatment of CHM mice with
AAV8.CBA.hCHM resulted in the improvement of pupillary response in the treated eyes of some animals, as
well as slowing of progression as judged by ophthalmoscopy. Histology of treated animals showed properly
localized expression of human REP-1 and a significant improvement in outer retina health as determined by
an increase in the thickness of the outer nuclear layer in treated eyes compared to controls. Combined, these
results indicate that transduction with AAV8.CBA.hCHM reduces the biochemical and pathogenic defects in
CHM both in vitro and in vivo and supports the application of AAV8 vectors in CHM gene therapy.
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ABSTRACT 
 
ADENO-ASSOCIATED VIRUS 8-MEDIATED GENE THERAPY FOR 
CHOROIDEREMIA: PRECLINICAL STUDIES IN IN VITRO AND IN 
VIVO MODELS 
 
Aaron Daniel Black 
Jean Bennett 
 
Choroideremia (CHM) is a slowly progressive X-linked retinal 
degeneration that results ultimately in total blindness due to loss of 
photoreceptors, retinal pigment epithelium, and choroid. CHM, the gene 
implicated in choroideremia, encodes Rab escort protein-1 (REP-1), which is 
involved in the post-translational activation via prenylation of Rab proteins. We 
evaluated AAV8.CBA.hCHM, a human CHM encoding recombinant adeno-
associated virus serotype 8 (rAAV8) vector, which targets retinal cells efficiently, 
for therapeutic effect and safety in vitro and in vivo in a murine model of CHM. In 
vitro studies assayed the ability of the vector to produce functional REP-1 protein 
in established cell lines and in CHM patient derived primary fibroblasts. Assays 
included Western blots, immunofluorescent labeling, and a REP-1 functional 
assay which measured the ability of exogenous REP-1 to prenylate Rab proteins. 
The in vivo work used unilateral subretinal delivery of AAV8.hCHM to treat a 
murine model of CHM, with the effects of treatment evaluated with pupillometry, 
v 
ophthalmoscopy, histology, and immunofluorescence analysis. The contralateral 
eye was treated with an AAV8.EGFP control. The results of the in vitro analysis 
demonstrated that the AAV8.CBA.hCHM vector was capable of inducing robust 
expression of REP-1 protein in a dose-responsive fashion in cultured cells, with 
the prenylation assay indicating that the exogenous REP-1 protein produced was 
capable of assisting in the activation of Rab proteins. This functional assay was 
also applied to CHM patient fibroblasts transduced with an AAV serotype 2 
version of the vector and demonstrated that exogenous REP-1 produced in these 
cells was functional. The in vivo subretinal treatment of CHM mice with 
AAV8.CBA.hCHM resulted in the improvement of pupillary response in the 
treated eyes of some animals, as well as slowing of progression as judged by 
ophthalmoscopy. Histology of treated animals showed properly localized 
expression of human REP-1 and a significant improvement in outer retina health 
as determined by an increase in the thickness of the outer nuclear layer in 
treated eyes compared to controls. Combined, these results indicate that 
transduction with AAV8.CBA.hCHM reduces the biochemical and pathogenic 
defects in CHM both in vitro and in vivo and supports the application of AAV8 
vectors in CHM gene therapy. 
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GENERAL INTRODUCTION  
 
CHOROIDEREMIA 
 
Disease Pathology 
 
Choroideremia (CHM) is a form of X-linked retinal disease which is 
characterized by the degeneration of the retinal pigment epithelium (RPE), 
photoreceptors, and choriocapillaris. In affected males, impaired night vision 
(nyctalopia) is apparent early in childhood and progressive loss of peripheral 
vision is also noted by the second decade of life. As the disease progresses, the 
visual field steadily constricts as retinal cells gradually die, and this eventually 
impinges on the central macula, the region of fine visual discrimination and color 
sensation. The disease culminates in complete blindness as early as the fourth 
decade of life. Initial diagnosis of new cases is remarkably simple, with 
fundoscopic imaging displaying a unique pattern of degeneration of peripheral 
RPE and retina, allowing the direct observation of the normally hidden choroid (1-
3). Confirmation is made by molecular diagnosis. Female carriers of the disease 
are typically asymptomatic, however, the fundus examination often reveals a 
patchy degeneration of the retina and RPE, likely due to lyonization (4). 
2 
The CHM Gene 
 
Choroideremia is caused by mutations in the CHM gene and results in the 
lack of expression of its protein product, Rab escort protein-1 (REP-1). The CHM 
gene is located at the Xq21.2 locus on the X chromosome and is composed of 15 
exons spanning an approximately 186Kb genomic region (5). The CHM mRNA is 
~5.5Kb and encodes a 653 amino acid protein, REP-1. 
REP-1 Protein 
 
A ubiquitously expressed protein, REP-1 plays an important role in cellular 
endocytosis and vesicular transport due to its involvement in the post 
translational modification of the Rab small GTPases (1, 5-8). Rab GTPases are 
members of the Ras superfamily and, when integrated with membranes, serve as 
controllers of tethering, docking, and fusion (9-10). In humans, more than 60 
Rabs have been so far identified (11). Before newly produced Rabs can integrate 
with membranes, they must be post-translationally modified through the addition 
of prenyl groups to 1-2 cysteines located near the C-terminus of the Rab protein. 
In order for this modification to occur, REP-1 must associate with the Rab 
GTPase and present it to Rab Geranylgeranyltransferase (Rab GGTase) for 
prenylation. Once prenylated, the Rab protein is escorted by REP-1 to its target 
membrane, REP-1 then disassociates and returns to the cytosol (1, 7-11). In 
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cells lacking REP-1, Rab GTPases are hypoprenylated, it is this shortage of 
functional Rabs which is thought to cause the CHM phenotype (9, 12-13).  
Molecular Basis of Disease 
 
Historically, there has been an ongoing debate as to the molecular causes 
of choroideremia pathology as well as the tissue types that are directly affected 
by the lack of REP-1 protein. Because Rab proteins are vital for proper cellular 
function throughout the body, it is immediately remarkable that individuals with 
CHM mutations do not display systemic disease, instead only showing a disease 
phenotype in their ocular tissues. It is thought that normal cellular function in the 
non-ocular tissues of CHM affected individuals is maintained thanks to the 
presence of Rab escort protein-2 (REP-2), a protein with many sequence 
similarities to REP-1. REP-2 is encoded by the autosomal CHM-like (CHML) 
gene, which bears a 71% homology to CHM. Like REP-1, REP-2 is expressed 
ubiquitously (14-15) and functions very similarly to REP-1, assisting in the 
prenylation and transport of Rab proteins. It is thought to substitute for REP-1 in 
most of the tissues of CHM patients (13-14). However, REP-2 does not assist in 
the prenylation of all Rabs to the same extent as REP-1, with certain Rabs, such 
as Rab27a, being prenylated much less efficiently when associated with REP-2 
(12-14). It is believed that some of the Rab proteins which are under-prenylated 
in ocular tissues are more vital for proper cellular function than in the rest of the 
body, resulting in cellular dysfunction and eventual death. 
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Precisely how a shortage of certain prenylated Rab proteins causes 
choroideremia has been hard for researchers to pin down. While tissue 
degeneration is observed in the choriocapilaris, RPE, and photoreceptors, these 
tissues are highly interdependent, and the loss of function of one can quickly lead 
to the collateral degeneration of the neighboring tissues (16). Therefore, it has 
been difficult to ascertain which cell types are degenerating in an autonomous 
manner, and which are degenerating due to the loss of neighboring tissues. 
Examining the retinas of female carriers of choroideremia has proven instructive 
in elucidating this problem, due to the lyonization of REP-1. In the female carrier, 
the wildtype version of REP-1 is expressed in some cells and the mutant version 
in others, resulting in a patchy appearance in the retina (17). This expression 
does not necessarily overlap for the RPE and photoreceptors, allowing for 
regions where the photoreceptors express REP-1, but, the underlying RPE does 
not, or vice versa (4). This situation allows us to examine the effects of REP-1 
loss in one tissue type, without the confounding effects of it also being lacking in 
the neighboring tissues. Post-mortem examinations of female carrier retinas have 
shown that the photoreceptor and RPE layers appear to degenerate 
independently, even when the neighboring layers still appear healthy (4, 18). 
Work in a conditional knockout animal model of the disease, wherein REP-1 
expression is eliminated in either the RPE or photoreceptors, supports these 
findings, demonstrating degeneration in both tissues regardless of the REP-1 
expression in the neighboring tissue (16, 19).  
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The molecular causes of degeneration in the RPE and photoreceptors of 
choroideremia patients have yet to be fully understood, and likely are not due to 
the same dysfunction in each cell type. Experiments in RPE cells with REP-1 
siRNA silencing have demonstrated slowed processing of phagocytosed 
photoreceptor outer segments due to defects in phagosome-lysosome fusion 
(20). It has also been observed that RPE melanosomes are not properly 
trafficked to the apical processes in REP-1 lacking cells in both a murine model 
of the disease and female carriers (4, 18, 21). In the photoreceptors, lack of 
REP-1 has been shown to result in inefficient opsin transport to the outer 
segments, a function essential to proper photoreceptor function (18). While these 
observed cellular dysfunctions may not all be culpable in cell death and vision 
loss, they do demonstrate that the delicate balance of intracellular transport is 
perturbed in both cell types, and help support the concept of cell autonomous 
degeneration in choroideremia. 
Choroideremia Murine Model 
 
No naturally occurring animal models of choroideremia have so far been 
identified, and the engineering of disease models has been hampered by 
differences in REP-1 necessity between humans and some species widely used 
for producing animal models (22-24). Attempts to produce murine CHM KOs 
proved embryonic lethal for both KO males and heterozygous females born from 
carrier mothers (22). The fact that heterozygous females who received the 
mutant gene from their mothers also were nonviable suggested that the lethality 
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may be due to impairment of extraembyonic tissue, such as the placenta, which 
is known to undergo paternal X chromosome silencing (22). Further research 
supported this hypothesis, with defective vascularization of the extra-embryonic 
tissue observed for affected embryos (24). CHM KO also proved embryonic 
lethal in zebrafish (23).  
As of this time, the only vertebrate model for choroideremia is a 
conditional mouse knockout of Rep1, where female mice are heterozygous for 
REP-1 KO, having inherited the mutant gene paternally (16, 22). Produced by the 
lab of Dr. Miguel C. Seabra, I will from here on refer to this strain as ChmWT/null. 
The ChmWT/null mouse model was generated by first creating a mouse strain with 
loxP sites flanking exon 4 of the Chm gene. This strain was then mated to mice 
who express Cre as a fusion protein with the tamoxifen-responsive estrogen 
receptor (MerCreMer). Resulting male mice who received both the floxed Chm 
gene and the MerCreMer gene undergo recombination of the loxP sites when 
treated with tamoxifen, this results in the excision of exon 4 of the Chm gene and 
the introduction of an early stop codon. By first treating these males with 
tamoxifen, and then mating them to wild-type females, female pups who are 
heterozygous for the Chm KO can be produced. Due to the embryonic lethal 
nature of Chm KO in mice, no male pups carrying the KO gene can be produced 
from this crossing. The heterozyous females produced in this manner exhibit a 
degeneration of the retina similar to but much more severe than the degeneration 
observed in human female CHM carriers, with patchy hypopigmentation, 
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progressive loss of RPE and photoreceptors, and reduced retinal/visual function 
in affected eyes (16). 
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GENE THERAPY 
 
Gene Therapy Methods Targeting the Genetic Basis of a Specific 
Disease 
 
Gene therapy directed at the molecular cause of a particular disease is 
approached by the editing of the mutations or the addition of a non-mutated copy 
of the disease-associated gene, methods respectively referred to as gene 
correction and gene augmentation. In gene correction, the general strategy is to 
induce a double stranded break (DSB) in the genome near the site of the 
deleterious mutation. This DSB initiates the homologous repair machinery for the 
genome and, if homologous sequences are available, the homologous repair 
machinery uses these as a template to replace the section where the double 
stranded break occurred. In normal cellular function, the most common template 
for homologous repair is the matching sequence in the sister chromatid, which 
results in an error free repair of the damaged sequence. In gene correction, this 
repair mechanism is co-opted by supplying an additional potential template in the 
form of a WT transgene cassette with flanking sequences homologous to the 
DSB site. In this case, it is also possible for the homologous repair machinery to 
use the transgene cassette as a template, thereby integrating it into the genomic 
sequence. Gene augmentation is substantially less complicated than gene 
correction. Rather than attempt to correct the genome itself, gene augmentation 
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seeks to simply supply the affected cells with a new WT copy of the mutated 
gene, which will be expressed in parallel with the cell’s endogenous copies of the 
gene. This method can work well for recessive mutations, but, often falters in the 
face of autosomal dominant disorders, wherein the disease phenotype is not 
caused by a lack of protein product, but, instead the presence of an innately 
harmful mutant protein product. Due to its simplicity and the prevalence of 
recessive genetic diseases, gene augmentation is currently the form of gene 
therapy for which we have the most experience. 
Non-viral 
Non-viral gene therapy methods focus on techniques to efficiently 
introduce DNA into cells without the use of viral vectors. The advantages of non-
viral gene therapy include avoiding potential immune responses to viral vector 
capsids and the ability to introduce transgene cassettes which are larger than the 
packaging capacity of commonly used viral vectors. A major area of research in 
non-viral gene transfer involves the complexing of DNA with cationic lipids or 
polymers. In this situation, the negatively charged phosphate groups on the DNA 
interact electrostatically with the positively charged amine groups present in the 
cationic compounds causing the DNA to form tight complexes with the cationic 
molecules (25-26). These cationic complexes then interact electrostatically with 
anionic cell membranes, facilitating endocytosis of the complexes (27-28). As the 
pH of the endosomes decrease, some DNA will manage to escape into the 
cytosol, where it then must make its way to the nucleus before the transgene can 
be expressed.  
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There are a number of challenges which still need to be overcome with 
regards to cationic lipid and polymer based systems. Both systems suffer from 
significant cytotoxicity, the reduction of which has been a major area of research 
(29-30). Efficient entry of transfected DNA into the nucleus is another point of 
difficulty and is currently thought to occur through a combination of diffusion 
during cell division, and directed transport through nuclear pores (31-34). In the 
case of cationic polymers, endosomal escape is another challenge, as the 
polymers do not possess the membrane destabilizing hydrophobic domains that 
lipids do (35). Despite their potential promise, these combined complications 
have led to cationic gene transfer not yet reaching the point where they are 
viable for clinical treatments. 
Retroviral 
Retroviral vectors are single stranded RNA viruses capable of transducing 
and integrating into the genomes of dividing cells (36-37). This genomic 
integration allows transgenes carried by retroviral vectors to be expressed long 
term in tissues with a high cell turnover rate. However, serious adverse events 
associated with this integration ability have led to retroviruses being viewed as 
undesirable vectors for gene therapy. 
 Retroviral vectors were the first viral vectors to be used in a successful 
clinical gene therapy, wherein a vector derived from the murine leukemia virus 
(MLV) gamma retrovirus was used to deliver a transgene expressing the γc 
cytokine receptor subunit ex vivo to hematopoietic stem cells of patients suffering 
11 
from X-linked severe combined immunodeficiency (38). This resulted in improved 
immune function in most of the treatment cohort (38-39). Unfortunately, later 
patient follow-ups discovered the clonal expansion T cells in 4 individuals, 
resulting in acute lymphoblastic leukemia (40-41). Further investigation 
demonstrated that the retroviral vectors were integrating near proto-oncogenes, 
resulting in their activation and oncogenic cell behavior (39, 41). Later studies 
show that MLV vectors have an integration target site preference for the 
transcriptional start regions of genes (42-43). This, combined with the gene 
activating properties of retroviral LTRs, resulted in the overexpression of genes 
immediately downstream of the integration site (44-46). 
Both due to their inability to transduce non-dividing cells, low viral 
production titers, and the occurrence of multiple cases of oncogenic insertional 
mutagenesis (39-41, 47), retroviral vectors are currently poor candidates for 
translational gene therapy applications. 
Lentiviral 
Lentiviral vectors are, in fact, themselves a subgroup of retroviral vectors, 
however, due to possessing significantly different transduction and integration 
profiles than MLV-based gamma retroviral vectors, they are typically referred to 
as a separate viral vector type. Unlike retroviral vectors, recombinant lentiviral 
vectors are capable of transduction and integration in non-dividing cells (48-49); 
they also can be produced at greater titers than recombinant retroviruses, 
allowing for easier production (50). Perhaps the greatest strength of lentiviral 
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vectors is their currently observed lack of harmful insertional mutagenesis. Unlike 
retroviral vectors, lentiviral vectors do not favor transcriptional start sites for 
genomic integration, instead, they prefer to integrate near genes which are 
already highly expressed within the cell (42, 51). Because most previous 
examples of insertional mutagenesis involve the activation of quiescent proto-
oncogenes by nearby enhancing LTRs, lentiviral transgenes favoring integration 
near already active genes should significantly reduce the chances of proto-
oncogene activation.  
Recent examples of successful lentiviral gene therapy include the 
treatment of Wiskott-Aldrick Syndrome (52-53), β-thalassaemia (54), X-linked 
adrenoleukodystrophy (55), and metachromatic leukodystrophy (56). Harmful 
insertional mutagenesis has yet to be observed in any of these trials, some of 
which have had upwards of 5 years of follow-up. This fact helps to bolster 
recombinant lentiviral vectors’ reputation as a safer method for integrating gene 
augmentation when compared to recombinant gamma retroviral vectors. 
However, there are additional features that would be desirable in lentiviral 
vectors, including the ability to target a more diverse set of cells and an 
expansion of its cargo capacity, so further improvements in vector design are 
warranted (46). 
Adenoviral 
Recombinant adenoviral vectors were at one time one of the most widely 
used clinical gene therapy vectors. This was due to a large transgene capacity of 
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approximately 36kb, the ability to transduce a wide range of dividing and non-
dividing cells, and lack of genomic integration, thereby avoiding potential 
insertional mutagenesis. Instead of genomic integration, the adenoviral genome 
persists in the cell nucleus as a replicating episome (57). The downside of this 
gene transfer method is that the episomes are rarely passed on to daughter cells, 
resulting in the loss of transgene production in cell populations with high turn-
over rates. However, in terminally differentiated cells and the appropriate 
immunologic milieau, these episomes can persist for many years, allowing for 
long term correction of genetic diseases (58).  
Adenoviral vectors dramatically fell out of favor at the end of the 20th 
century in what would be the first known death due to gene therapy (59). In 
September of 1999 a patient named Jesse Gelsinger, with partial ornithine 
transcarbamylase (OTC) deficiency received a high dose recombinant adenoviral 
vector expressing the OTC protein as part of a gene therapy pilot study. 18 hours 
following vector infusion in the portal vein Jesse Gelsinger began to show signs 
of confusion and jaundice and by 35 hours he was intubated and responsive to 
deep pain only. At 98 hours he was removed from life support and expired. 
Cause of death appeared to be due to a massive systemic innate immune 
response to the recombinant vector. The fallout from this event was immense, 
with a collapse in gene therapy’s public opinion and a substantial increase in 
regulations pertaining to gene therapy. It took years for gene therapy research in 
the US to recover, and adenoviral vectors are now considered better candidates 
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for immunologic application (such as vaccination or anti-cancer approaches) than 
for gene augmentation therapy. 
Adeno-associated virus 
Recombinant adeno-associated viruses (rAAVs) are currently a favored 
viral vectors for gene therapy due to their low immunogenicity, ability to 
transduce dividing and quiescent cells, natural replication incompetence, and 
lack of genomic integration. There is also an excellent safety profile for these 
vectors. AAVs were first isolated as contaminants of adenovirus preparations in 
the 1960s (60), and were later demonstrated to neither cause disease nor to be 
capable of replication without concurrent adenoviral infection (61-62). Wild-type 
(WT) AAV has a single stranded DNA (ssDNA) genome of ~4.7Kb and is non-
enveloped. It is a member of the parovirus family in the dependovirus genus. 
While WT AAV has been shown to undergo site specific genomic integration 
(63), rAAV vectors are prominently non-integrating, with their genomes instead 
existing in the nucleus as episomes (64). These episomes do not replicate upon 
cell division, thus in cells with constant turnover, rAAV transgene expression will 
soon be lost due to dilutional effects. This makes rAAV vectors best suited either 
for cases requiring transient expression, or the transduction of terminally 
differentiated cells with little or no turnover. Due to their terminally differentiated 
state and low turnover, this makes many of the cell types in the retina, including 
the RPE and phototreceptors, well suited for transduction with rAAV vectors.  
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The tissue tropism and transduction efficiency of rAAV can be greatly 
affected by the serotype of AAV used (65-66). For the retinal gene therapy trials 
targeting the form of Leber’s congenital amaurosis (LCA) due to RPE65 
mutations, the AAV2/2 serotype was utilized. In this nomenclature the first 
number indicates the serotype of the viral genomic sequence, while the second 
number indicates the serotype of the capsid used. AAV2/2 shows preferential 
transduction of the RPE, with lower transduction of rod photoreceptors and little 
to no transduction of cone photoreceptors (67-68). In the case of LCA-RPE65, 
this was ideal, as the retinal degeneration exhibited in LCA-RPE65 originates 
from RPE dysfunction. However, in situations where degeneration occurs in more 
than one cell type autonomously, such as may be the case in CHM, serotypes 
which show broader and more equal tissue transduction in the retina are 
desirable. Of the current tested serotypes, AAV5 and AAV8 both show improved 
transduction of the RPE and photoreceptors when compared to AAV2 (69-70), 
and, along with AAV9, demonstrate transgene expression in cone 
photoreceptors, which are not transduced by AAV2 (70). 
Retinal Gene Therapy 
 
The retina is an ideal target for gene therapy for a number of reasons. The 
retina forms as an outpouching of the brain and thus possesses the blood-brain 
barrier, which restricts the penetraion of many substances into or out of this 
tissue. It is immunoprivileged, with the aqueous humor containing factors which 
suppress the innate immune response and promote regulatory activity which 
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desensitizes the adaptive immune system to foreign antigens within the eye (71-
73). Finally, the retina is a relatively small organ to treat and possesses 
contralateral redundancy, providing both a control for the treated eye and a 
reserve if the treatment harms visual function. Also, the doses used to treat the 
retina are much smaller than those that would be used to treat a systemic 
disease.  
The retina was the target of one of several successful human gene 
therapy trials, for the treatment of Leber’s congenital amaurosis 2 (LCA2), a 
congenital retinal dystrophy caused by a lack of the RPE65 protein product (74-
75). The disease is congenital and is thus one of the most severe forms of retinal 
degeneration. There is significant impairment of vision and random eye 
movements (nystagmus) observed in infancy and complete blindness occurs in 
mid to late adulthood. RPE65 is expressed almost exclusively within the RPE of 
the eye, where it is vital for the production of 11-cis retinal, a molecule necessary 
for the proper function of the photoreceptors. Lack of 11-cis retinal quickly leads 
to the dysfunction and death of photoreceptors as well as the loss of the RPE in 
affected individuals. Multiple concurrent gene therapy trials were undertaken to 
supplement mutant endogenous copies of RPE65 in LCA2 patients with 
transgenes expressing the wild-type copy of RPE65 (75-78). rAAV vectors were 
used in all trials due to the terminally differentiated nature of the RPE, the low 
immunogenicity exhibited by rAAV, and the relatively small size of the RPE65 
transgene being within the limits of rAAV vector capacity. In the years following 
the studies most patients showed improved visual function, especially among 
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younger members of the treated cohorts who had greater levels of persisting 
RPE and photoreceptors at the time of treatment (75, 79-80). No negative 
outcomes due to immune response to either the rAAV capsid or transgene were 
observed in the trials, and in one trial it was shown that there was a benign 
immune response even after treatment of the contralateral (previously 
uninjected) eye as well (81). Further, improvements in retinal and visual function 
were observed in the majority of the newly treated eyes. 
The success in the LCA-RPE65 trials, as well as the lack of severe 
adverse events associated with vector administration, has spurred researchers 
on to test viral gene therapy in other congenital and progressive retinal 
dystrophies. Diseases for which recombinant vectors are currently in clinical trial 
include exudative age related macular degeneration, Usher syndrome, Stargardt 
disease due to ABCA4 dysfunction, and MERTK-associated autosomal recessive 
retinitis pigmentosa. There is also a clinical trial in progress targeting 
choroideremia (82). 
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MATERIALS AND METHODS 
 
Generation of a recombinant adeno-associated virus (AAV) carrying the 
full-length human REP-1-encoding cDNA 
A recombinant AAV proviral plasmid carrying the wild type human CHM 
cDNA (hCHM), pAAV.CBA.hCHM, was generated by cloning the human CHM 
cDNA into the transgene cassette harbored in an AAV proviral plasmid such that 
it was placed under control of the cytomegalovirus immediate early enhancer, the 
proximal chicken β actin (CBA) promoter, and CBA intron 1 sequences flanking 
the CBA exon 1. The proviral plasmid also contains AAV2 inverted terminal 
repeats and a bovine growth hormone-derived PolyA sequence (Figure 1). The 
proviral plasmid backbone contains a 4.7 Kb lambda phage fragment stuffer 
followed by the kanamycin bacterial selection gene and the bacterial origin 
(Figure 1). The proviral plasmid was used to generate recombinant AAV2 and 
AAV8 vectors by triple transfection of HEK293T cells using a helper plasmid 
encoding the AAV2 or AAV8 capsid, respectively. The AAV2.CBA.hCHM and 
AAV8.CBA.hCHM vectors were generated by the research vector core facility at 
the Center for Cellular and Molecular Therapeutics at the Children’s Hospital of 
Philadelphia (CHOP). DNA sequences were confirmed by sequence analysis. 
The control vector, AAV8.EGFP, was provided by the Penn Vector Core facility. 
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Cell lines and tissue culture conditions 
CHO cells were cultured in Ham’s F-12K (Kaighn’s) (Invitrogen, Carlsbad, 
CA) with 10% FBS and 1% penicillin/streptomycin (Invitrogen, Carlsbad,CA). 
COS-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 
4.5 mg/L glucose and 10% FBS (Invitrogen, Carlsbad,CA).  All cells were grown 
at 37°C and 5% CO2. Transfections in the cells were carried out using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) or Fugene-6 transfection reagent 
(Roche applied Sciences, Indiana Police, IN) according to the manufacturer’s 
protocol.  
Immunofluorescence analysis 
Immunofluorescence of cell cultures was performed using the monoclonal 
REP-1 antibody 2F1 (1:500, sc-23905, Santa Cruz Biotechnology, Santa Cruz, 
CA). Immunofluorescence of retinal cryosections was performed using a 
polyclonal REP-1 antibody (1:500 dilution, HPA003231, Sigma, St. Louis, MO). 
Fluorescence was visualized with a Zeiss Axio Imager .M2 microscope and 
captured using an Axiocam MR camera with Axiovision software (Carl Zeiss 
Microscopy, LLC, Thornwood, NY).  
Assessment of transgene production and activity 
In order to verify the ability of AAV8.CBA.hCHM to produce exogenous 
human REP-1 in vitro we infected CHO cells at multiple MOIs with the vector. 
CHO cells were infected with AAV8.CBA.hCHM at 1E4, 1E5, or 1E6 vector 
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genomes (vg) per cell. Cells were harvested 48 h post-infection. Western blot 
analysis was performed using the anti-REP-1 2F1 antibody (1:1000, see above) 
as the primary antibody and a secondary HRP conjugated anti-mouse IgG 
antibody (1:5000, NA931-1ml, Amersham Biosciences, Piscataway, NJ). The 
blots were developed by the chemiluminescent method using ECL reagents 
according to the manufacturer's instructions. 
An in vitro prenylation assay was performed using [3H]-geranylgeranyl 
pyrophosphate (GGPP) (Perkin Elmer, Boston, MA, USA) as a prenyl group 
donor, in the presence of recombinant Rab geranylgeranyl transferase  and 
Rab27 (Blue Sky Biotech, Worcester, MA) as previously described (83). 
Incorporation of radiolabeled prenyl groups into Rab27 was measured by 
scintillation counting using a Beckman Coulter LS 6500 (Beckman Coulter, Brea 
CA). All experiments were performed in triplicate, and statistical comparison of 
prenylation between experimental and control groups was evaluated using 
Student’s t-test. Two different prenylation assays were performed. In one, COS-7 
cells were transduced at 1E6 MOI with AAV8.CBA.hCHM, the functional assay 
was then performed on cell lysates. Endogenous REP-1 is present in COS-7 
cells, and the assay was performed with the idea that overexpression of 
exogenous REP-1 would result in a significant increase in prenylation in the 
treated group. The other cells transduced were primary fibroblasts from 
choroideremia-affected individuals. These cells had been collected under an 
approved Institutional Review Board protocol, #808828. We found that AAV8 
does not efficiently transduce primary fibroblasts. Therefore, we generated an 
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AAV2.CBA.hCHM vector using the same proviral plasmid. Primary fibroblasts 
were transduced with AAV2.CBA.hCHM at an MOI of 1E6 and cell lysates were 
subsequently assayed for prenylation activity. Data are presented as the mean ± 
Standard deviation (SD). P values were calculated using the 2-tailed Student’s t 
test. A P-value less than <0.05 is considered as a statistically significant value. 
Animal Studies 
Animal studies were carried out under an Institutional Animal Care and 
Use Committee-approved protocol, 200902. A limited number (n=18) of 
heterozygous female ChmWT/null mice were available for long-term follow-up. Mice 
were maintained on a 12 h light- dark cycle.  Mice were anesthetized with 
ketamine/xylazine and 1E9 AAV8.CBA.hCHM in ~1 μl DPBS was delivered 
subretinally when they were 6 weeks of age (84). The contralateral eye was 
injected with the same concentration of AAV8.EGFP as control.  
Pupillometry: Measures of the amplitude of the pupillary light reflex were 
performed serially following injection. Mice were dark adapted for 24 hours 
before analysis. A NeurOptics A-1000 Pupillometer (NeurOptics Inc., Irvine, CA) 
was used to measure changes in pupillary diameter of eyes of the AAV8-injected 
mice over time following exposure to five 0.1 second flashes of 4.5 μW/cm2 
intensity at 10 second intervals. Spurious lines due to eye blinks were manually 
removed. 
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Retina fixation, cryosectioning, and histology: At 50 weeks of age 
ChmWT/null mice were sacrificed, eyes harvested, and fixed in 4% PFA. Eyes were 
then cryoprotected, embedded in Optimal Cutting Temperature (OCT) media 
(Fisher Scientific), and frozen. Cryosections were made using a Leica CM1850 
cryostat (Leica Microsystems, Wetzlar, Germany). Retinal sections were then 
stained with hematoxylin and eosin (H&E) or evaluated for REP-1 protein by 
immunofluorescence. The number of rows of nuclei in the ONL was measured at 
6 prescribed points throughout the retina, and then these were compared for 
control and AAV8.CBA.hCHM treated retinas. Thicknesses of designated regions 
of the retina were graphically compared as the mean ± standard deviation (SD), 
while total nuclear thickness was presented as the median. P values were 
calculated using signed rank tests and paired t-tests for medians and means 
respectively. A P-value less than <0.05 is considered as a statistically significant 
value. 
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PRODUCTION AND IN VITRO FUNCTIONAL 
VERIFICATION OF A REP-1 PRODUCING AAV 
VECTOR 
 
SUMMARY 
 
Choroideremia is an X-linked congenital retinal dystrophy caused by 
mutations in the CHM gene which result in the lack of expression of its protein 
product Rab escort protein-1 (REP-1). In choroideremia patients, there is a 
progressive loss of vision and the disease is symptomatic in the first decade of 
life with nyctalopia. By the end of the second decade loss of peripheral vision is 
usually observed, causing a progressive constriction of the visual field which 
culminates in complete loss of vision as early as the 4th decade. In the ocular 
tissues, degeneration of the choriocapilaris, RPE, and photoreceptors are 
observed, with the loss of retinal layers beginning in the peripheral retinal and 
slowing constricting upon the fundus. 
In this study we produced pAAV.CBA.hCHM, a rAAV proviral plasmid with 
the human CHM cDNA under the control of a constitutive chicken beta-actin 
(CBA) promoter. Initial transfection experiments in Chinese hamster overy (CHO) 
cells with the proviral construct revealed robust expression of REP-1 in 
transfected cells via western blot. An AAV8 version of the vector was then 
produced from the proviral plasmid and also showed strong REP-1 expression 
when transducing CHO cells. 
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A REP-1 functional assay was then developed and used to test lysates 
from AAV8.CBA.hCHM transduced cells, with a nearly 2-fold increase in REP-1 
activity observed. Attempts to test AAV8.CBA.hCHM in CHM patient primary 
fibroblasts initially failed because fibroblasts are not efficiently transduced by the 
AAV8 serotype. In order to cope with this, we used the same pAAV.CBA.hCHM 
proviral plasmid to produce an AAV2 serotype version of the vector, 
AAV2.CBA.hCHM. The AAV2 serotype is capable of transducing primary 
fibroblasts, and functional analysis of lysates from AAV2.CBA.hCHM transfection 
patient fibroblasts indicated a 3-fold increase in REP-1 activity as compared to 
untransduced cells. 
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INTRODUCTION 
 
Choroideremia (CHM) is an X- linked inherited retinal disease which 
typically presents in childhood with nightblindness (nyctalopia) and progresses 
rapidly during adolescence and young adulthood to destroy peripheral vision. 
Central vision (visual acuity) often remains good until mid-life, but then is also 
ultimately affected. Choroideremia is often diagnosed by the unique appearance 
of the retinal fundus, which shows scalloped areas of confluent loss of retinal 
pigment epithelium (RPE) and choriocapillaris. Underlying photoreceptors in 
these areas degenerate as well. These changes are readily apparent with 
ophthalmoscopy and can be confirmed by fluorescein angiography and optical 
coherence tomography (OCT). Female carriers of the disease often show a 
patchy degeneration in the fundus, and can also be symptomatic, although 
usually their findings are subclinical. The extent of disease in carriers is affected 
by the extent of retinal cell lyonization (random X chromosome inactivation). 
Choroideremia is caused by loss-of-function mutations in the CHM gene, 
which encodes the protein Rab escort protein-1 (REP-1). REP-1 consists of 653 
amino acids with a molecular weight of ~83 kDa. There are more than 110 known 
mutations in CHM, including nonsense, splicing, deletions, and insertions (85). 
Most of these mutations result in a lack of production of the REP-1 protein and 
the remainder, presumably, result in its loss-of-function. The lack of production of 
the REP-1 protein forms the basis of a commonly used test to diagnose this 
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condition (86). REP-1 plays a key role in the post-translational lipid modification 
of Rab small GTpases(Rabs) (87). Rabs are members of the Ras superfamily 
and, when integrated with membranes, serve as controllers of tethering, docking, 
and fusion (88). Before newly produced Rabs can integrate with membranes, 
they must be post-translationally modified through the addition of prenyl groups 
to 1-2 cysteines located near the C-terminus of the Rab proteins. In order for 
these modifications to occur, REP-1 must associate with Rab GTPases and 
present them to Rab Geranylgeranyltransferase (Rab GGTase) for prenylation. 
Once prenylated, the Rabs are escorted by REP-1 to their target membrane, 
REP-1 then disassociates and returns to the cytosol (87). Lack of REP-1, as 
observed in CHM, leads to the accumulation of unprenylated, and hence 
nonfunctional, Rab proteins, causing the CHM phenotype (12-13). 
Choroideremia is an ideal target for gene therapy for a number of reasons. 
It is a monogenetic disease, whose cDNA has already been successfully cloned. 
Initial diagnosis is quicker and simpler than with most forms of inherited 
blindness, due to the readily identifiable unique pattern of retinal degeneration. 
The degeneration is slow and significant impairment in vision is generally not 
recognized until the second decade of life, allowing for a large window of time for 
potential intervention and allowing use in a clinical trial of adult subjects. Finally, 
the effects of choroideremia are isolated to the eye, an ideal target for gene 
therapy due to its immunoprivileged state, small size, and relative physical 
isolation from the rest of the body (89-90). Proof of concept of gene 
augmentation therapy has been successfully performed in dozens of animal 
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models for different retinal diseases (91-92) and the retina was one of the first 
organs in which gene therapy was found to be successful in humans (74, 76, 80, 
92-94). 
Proof-of-concept of gene augmentation therapy for CHM was first 
described using a first generation recombinant adenoviral vector. This vector  
successfully rescued REP-1 function in lymphoblasts and fibroblasts isolated 
from affected individuals, showing both robust protein expression and function in 
cell culture (95). However, the adenoviral vector is not ideal for human 
application due to the transient nature of adenovirus-mediated gene transfer and 
the potential for a toxic inflammatory response (59, 96). Tolmachova et al have 
used both a recombinant lentivirus and a recombinant adeno-associated virus 
(AAV) serotype 2 (AAV2) to test for rescue and these have proven effective in 
restoring REP-1-mediated prenylation activity in vitro and in vivo (97-98). 
Lentivirus preferentially transduces RPE (99) and carries a risk of insertional 
mutagenesis (41). Recombinant adeno-associated virus vectors, however, have 
a strong safety and efficacy record in both animals and humans, and, by 
modifying the AAV capsid, one can target a diverse set of retinal cells and control 
onset of expression (89, 100). More than half a dozen human clinical trials 
targeting retinal disease are now in progress using AAV2 (http://clinicaltrials.gov), 
including one targeting choroideremia. Because AAV serotype 8 (AAV8) targets 
photoreceptors more efficiently than AAV2  and thus could potentially be used at 
a lower dose to treat choroideremia (101), we carried out proof-of-concept 
studies using that vector. AAV8, like AAV2, also targets RPE cells efficiently. 
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We carried out preliminary tests of safety and efficacy in a mouse model 
of choroideremia. Since knockout of the murine Chm gene is embryonic lethal, 
we used a conditional knock-out mouse generated using the Cre/loxP system of 
site-specific recombination (102). In this model, heterozygous null female carriers 
exhibit hallmarks of CHM: slowly progressive degeneration of the photoreceptors, 
patchy depigmentation of the RPE, and similar biochemical deficits as are found 
in CHM patients. 
Our results show that administration of AAV8.CBA.hCHM reverses the 
prenylation defect and sustains retinal morphology and function in vivo. There 
was no inflammation or other sign of toxicity in retinas injected subretinally with 
AAV8.CBA.hCHM. These results establish the potential therapeutic use of 
AAV8.CBA.hCHM constructs in treating retinal degenerations caused by lack of 
functional REP-1 protein in choroideremia. 
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RESULTS 
 
Expression of AAV8.CBA.hCHM in cultured cells 
To verify the appropriate expression of the wildtype human CHM protein 
encoded in the proviral construct (Figure 1), CHO cells were transfected with 
pAAV.CBA.hCHM and western blot analysis was performed using the human 
REP-1 specific 2F1 antibody. A band of the expected size (83 kDa) for human 
REP-1 was observed in transfected cells with no band observed in control, 
untransfected cells (Figure 2). The pAAV.CBA.hCHM proviral plasmid was then 
used to produce a recombinant AAV8 serotype vector using the triple transfection 
method. In order to verify that transfection with AAV8.CBA.hCHM would result in 
the production of exogenous REP-1, we transduced aliquots of CHO cells with 
1E4, 1E5, or 1E6 vector genomes (vg) per cell. 48 h later, cell lysates were 
collected and analyzed via western blot using 2F1 antibody. A clear dose 
dependent production of human REP-1 was observed in the transduced cell 
lysates (Figure 3), while lysates from untransduced cells showed only very faint 
expression, likely due to 2F1 cross-reactivity to endogenous REP-1. 
Verification of exogenous REP-1 function in cultured cells 
In order to verify function of the human REP-1 produced by 
AAV8.CBA.hCHM, we compared REP-1 activity in vector-treated COS-7 cells to 
that of untreated cells. COS-7 cells were infected with AAV8.CBA.hCHM at an 
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MOI of 1E6 vg/cell and over-expression of human REP-1 in the treated cells was 
confirmed via western blot (Figure 4A) and immunofluorescence (Figure 4B) 
using the 2F1 antibody. Results of both these assays demonstrated elevated 
levels of REP-1 protein in the cells when compared to endogenous levels. 
Cell lysates from AAV8.CBA.hCHM treated and control cells were then 
assayed for REP-1 activity by measuring the ability of REP-1 in the cell lysates to 
prenylate exogenous Rab27. Lysates from transduced cells showed a nearly 2 
fold increase in Rab27 prenylation over control cells (Figure 5, P=0.0034), clearly 
illustrating that the exogenous human REP-1 produced by the AAV8.CBA.hCHM 
vector is capable of normal REP-1 function with regards to the prenylation of Rab 
proteins. 
We attempted to demonstrate functional REP-1 expression in 
AAV8.CBA.hCHM-infected cells derived from individuals with choroideremia. 
Unfortunately, the AAV8 serotype poorly transduces primary fibroblasts rendering 
it unfit for use in such an experiment. Instead, we produced an AAV2 serotype 
derived from the same proviral plasmid. We successfully transduced CHM 
patient primary fibroblasts at an MOI of 1E6 AAV2.CBA.hCHM. Cell lysates were 
then assayed for REP-1 activity and the results indicated an almost 3-fold 
increase in Rab27 prenylation in transduced cells as compared to control (Figure 
6, P=0.017). 
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DISCUSSION 
 
It has previously been concluded that choroideremia is caused by the lack 
of REP-1 protein expression or function in retinal cells, and, more specifically, the 
reduction in functional Rab proteins due to lack of REP-1 to facilitate prenylation. 
Therefore, in order to treat choroideremia via gene therapy, it is necessary to 
design a platform for initiating the production of WT functional REP-1 in retinal 
cells.  
Viral vector gene therapy is currently the most effective means with which 
to deliver transgenes to cells in vivo, and rAAV vectors have previously been 
demonstrated to be capable of delivering transgenes for prolonged expression in 
terminally differentiated retinal tissues. In this study we have produced a rAAV 
vector expressing the human REP-1 gene under the control of a constitutive CBA 
promoter. This construct, as a proviral plasmid, was capable of strong expression 
of human REP-1 in CHO cells following transfection with a cationic liposome 
reagent. A rAAV2/8 vector, AAV8.CBA.hCHM, was produced using this proviral 
plasmid and further experiments in CHO cells demonstrated a robust REP-1 
expression dose response following transduction at varying MOIs. 
While the verification of REP-1 expression via Western blot was 
heartening, it was desirous to verify that the exogenous REP-1 produced from 
AAV8.CBA.hCHM was capable of normal REP-1 function, namely the prenylation 
and activation of Rab proteins. In order to determine this, we devised a functional 
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assay for REP-1, wherein lysates from transduced cells were used in an in vitro 
prenylation assay which would radiolabel Rab proteins in the presence of 
functional REP-1. This functional assay scales with the amount of functional 
REP-1 available, allowing the assay to be used in cases of REP-1 over-
expression in cells already containing endogenous REP-1 as well as for 
expression in cells lacking endogenous REP-1. Via this assay, we demonstrated 
that the AAV8.CBA.hCHM vector was capable of producing functional REP-1 in 
COS-7 cells, with rates of Rab prenylation in transduced cells being nearly 2 
times that observed in cell lystates containing only endogenous REP-1. Initial 
attempts to measure REP-1 activity in transduced CHM patient fibroblasts proved 
unsuccessful, as it soon became clear that the AAV8 serotype, while excellent for 
transducing retina tissue, was not capable of transducing primary fibroblasts 
efficiently. Previous work in our lab has indicated that primary fibroblasts are 
more permissive to transduction by AAV2, so we used the proviral 
pAAV.CBA.hCHM plasmid to produce an AAV 2 serotype vector. As predicted, 
this new vector efficiently transduced CHM patient fibroblasts, and produced 
functional human REP-1 protein as observed via Western blot and Rab 
prenylation assay. While this AAV2.CBA.hCHM vector possess a different 
serotype than the AAV8.CBA.hCHM used previously, it is produced using the 
same proviral plasmid and carries an identical transgene, thus, results gained 
from it pertaining to the transgene product should apply equally to 
AAV8.CBA.hCHM.  
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In conclusion, we have demonstrated that an AAV8 vector encoding the 
human CHM gene is capable of expression robust levels of functional REP-1 
protein in vitro in both established cell lines and primary patient fibroblasts. This 
is an important step towards the potential use of an AAV8 gene therapy vector 
containing a CHM transgene to treat CHM in humans. 
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FIGURES 
 
 
Figure 1. Generation of a CHM expression vector, pAAV.CBA.hCHM. 
Schematic of the AAV proviral plasmid, carrying human CHM under the control of 
the cytomegalovirus enhancer chicken βactin (CBA) promoter. Flanking inverted 
terminal repeats (ITR) guarantee proper packaging of the transgene cassette into 
AAV capsids while the replication origin (ori) and kanamycin resistance gene 
(KanR) allow for efficient production of the plasmid transformed bacteria. 
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Figure 2. Western blot verification of expression from pAAV.CBA.hCHM. 
Immunoblot reveals no REP-1 protein in control, untransfected, CHO cells, while 
there is a band of the expected size of REP-1 (83 kDa) in CHO cells transfected 
with pAAV.CBA.hCHM. 
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Figure 3. Dose response analysis of AAV8.hCHM AAV8 vector in vitro. 
AAV8.CBA.hCHM vector was used to infect CHO cells at 1E4, 1E5 or 1E6 
vg/cell. Immunoblot shows a clear dose dependent production of human REP-1 
in the transduced cell lysates, whereas lysates from untreated cells showed only 
very faint expression, likely as a result of 2 F1 cross-reactivity to endogenous 
REP-1. 
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Figure 4. Immunoblot and immunofluorescence of COS-7 cells transduced 
with AAV8.CBA.hCHM. 
AAV8.CBA.hCHM was used to transduce COS-7 cells with 1E6 vg/cell and 
expression of human REP-1 was verified by western blotting (A) and (B) 
immunofluorescence. 
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Figure 5. Verification of exogenous REP-1 function from AAV8.CBA.hCHM 
transduced COS-7 cells. 
Cell lysates from AAV8.CBA.hCHM and control COS-7 cells were assayed for 
REP-1 activity using a prenylation assay. There is an almost two-fold increase in 
Rab27 prenylation in transduced compared to control cells (p=0.0034). These 
assays demonstrate greatly elevated levels of functional REP-1 protein in COS-7 
cells after transduction with AAV8.CBA.hCHM compared to endogenous levels. 
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Figure 6. Verification of exogenous REP-1 function from AAV8.CBA.hCHM 
transduced choroideremia patient fibroblasts. 
Unfortunately AAV8.CBA.hCHM (1E6 vg/cell) does not efficiently transduce CHM 
patient fibroblasts. Therefore, we produced an AAV2 serotype of or vector, 
AAV2.CBA.hCHM, as the AAV2 serotype has previously been observed to 
transduce human fibroblasts successfully. Patient fibroblasts treated with 
AAV2.CBA.hCHM at 1E6 vg/cell showed an almost three-fold increase in REP-1 
activity compared to control (p=0.017). 
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TREATMENT OF A CHOROIDEREMIA MURINE 
MODEL WITH A REP-1 PRODUCING AAV VECTOR 
 
SUMMARY 
 
In this study we subretinally injected 6 week old CHMWT/null mice in one 
eye with our experimental vector AAV8.CBA.CHM, while contralateral eyes were 
injected with an AAV8.EGFP control. The pupillary responses of treated mice 
were assayed regularly via pupillometry until the mice were 50 weeks of age, 
with clear divergences in response between treated and control eyes becoming 
apparent at approximately 32-39 weeks of age in some animals. At 50 weeks of 
age the mice were sacrificed and retinal tissue harvested and cryosectioned. 
Immunostaining analysis of treated and control retinal sections demonstrated 
expression of human REP-1 protein in the photoreceptors and RPE of treated 
retinas, with no corresponding expression in control eyes. Analysis of H&E 
stained retinas showed a significant difference in retinal health between treated 
and untreated eyes, with ONL layer thickness being significantly higher in treated 
retinas as compared to untreated retinas. 
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INTRODUCTION 
 
The road to the production of an animal model for CHM has not been a 
smooth one. Initial attempts to produce a murine animal model, the Chmnull/Y 
mouse, revealed that lack of Chm in mice is embryonic lethal, with the 
malformation of placental extra-embryonic tissue appearing to be the cause (24). 
It was also discovered that ChmWT/null mothers were incapable of producing 
carrier female offspring when crossed with WT males, likely due to the 
inactivation of the paternal X-chromosome in murine extra-embryonic tissue 
(103-104). This theory was supported by the discovery that Chmnull/WT and 
Chmnull/Y embryos produced by ChmWT/null females crossed with WT males could 
be rescued by aggregation at the 8-cell stage with tetraploid WT embryos. The 
aggregation, referred to as a tetraploid complementation assay, exploits the fact 
that tetraploid embryos are capable of forming extra-embryonic tissue, such as 
the placenta, but not a functional fetus. By aggregating these tetraploid cells with 
mutant diploid embryos it is possible to rescue extra-embryonic defects in these 
mutant embryos, verifying that defects in extra-embyronic development are the 
cause of the embryonic lethality (105). Unfortunately, large scale production of a 
disease model by the use of a tetraploid complementation assay is not viable, 
and a different method needed to be found. The solution occurred when it was 
observed that ChmWT/null females exhibited a slow patchy degeneration of their 
retinas similar to that observed in human female carriers of CHM (22). This 
patchy degeneration is ascribed to the lyonization of cells within female retinas, 
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wherein the X-chromosome of one chromatid is inactivated throughout the cells 
of the retina. This results in a diffuse degeneration of the retina where some cells 
are dysfunctional and others are not. Lyonization need not be uniform, and can 
differ between animals, potentially resulting in some animals displaying greater 
degeneration than others. Unlike in human female carriers, the degeneration 
observed in murine carriers is not asymptomatic, and by 6 months of age the 
mice display aberration in electroretinograms and significant thinning of the ONL 
(16). 
Our lab has previously produced an AAV serotype 8 vector which 
expresses the human REP-1 gene under the control of the CBA promoter. This 
vector has been shown to produce functional human REP-1 protein in COS-7 
cells and an AAV2 serotype version of the vector did the same in CHM patient 
fibroblasts. While the AAV2 serotype already has a successful history as a gene 
therapy vector, it demonstrates a marked transduction preference in the retina for 
the RPE, with much less targeting of the photoreceptors. Choroideremia is a 
disease which causes dysfunction and autonomous degeneration in both the 
RPE and photoreceptors, which makes it highly desirable to use a vector which 
will target both cell types well at reasonable vector doses. The AAV8 serotype 
has been shown to target both the RPE and photoreceptors in murine and non-
human primate models and results in expression of transgenes in both tissue 
types at higher levels than observed with AAV2 at equivalent vector doses (106). 
Because of this, we chose to use an AAV2/8 serotype for our animal studies. 
43 
In this study, we subretinally injected ChmWT/null mice with 
AAV8.CBA.hCHM in one eye, and contralaterally with AAV8.EGFP as a control. 
Animals were then monitored via ophthalmoscopy and pupillometry until 
sacrifice, after which retinal tissue was harvested and analyzed. 
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RESULTS 
 
Safety of subretinal injection of AAV8.CBA.hCHM 
ChmWT/null mice were injected unilaterally and subretinally with 1E9 vg of 
AAV8.CBA.hCHM. The mice were evaluated by ophthalmoscopy at baseline, 1 
week after injection, and at monthly intervals thereafter. There was no evidence 
at any timepoint of inflammation resulting from exposure to the experimental or 
control vector. Media remained clear and the retina had reattached by the first 
post-operative examination. The ChmWT/null retinas before and after treatment 
with AAV8.CBA.hCHM showed diffuse small hypo-pigmented lesions (Figure 7). 
Lesions remained similar in size in the case of AAV8.CBA.hCHM-injected eyes 
but expanded in size in AAV8.EGFP-injected eyes (Figure 7). Retinas that had 
been injected subretinally with the AAV8.EGFP control vector possessed high 
levels of EGFP protein by the first post-operative examination and continuing 
through the latest timepoint (Figure 7). 
Pupillometry and histology results indicate efficacy in Chmnull/WT mice 
Analysis of retinal function in experimental and control eyes was 
performed regularly and non-invasively using evaluation of the amplitude of the 
pupillary light reflex (PLR) following injection. While the PLR was similar between 
treated and control eyes at baseline, differences in response appeared between 
32 and 39 weeks of age with diminished responses in the control eyes. (Figure 
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8). The amplitude of the PLR was similar in ChmWT/null AAV8.CBA.hCHM-injected 
eyes as in untreated eyes of age-matched wildtype mice (Average amplitude in 
AAV8.CBA.hCHM-injected ChmWT/null eyes was 0.39 mm; Average amplitude in 
wildtype mice was 0.34 mm, P= 0.08).  
At 50 weeks of age, the mice were sacrificed and their eyes harvested and 
cryosectioned. Histology displayed severe loss of the photoreceptors (decrease 
in outer nuclear layer thickness) in control retinas (Figure 9B).  In the 
AAV8.CBA.hCHM-treated retinas, degeneration was significantly stalled, as 
evidenced by an average of 7 rows of photoreceptor nuclei in the outer nuclear 
layer (ONL) versus <1 row of nuclei in the control retinas (Figure 9E). Measures 
of retinal thickness across the retina (Figure 10) showed an increased ONL 
thickness for all retinal points in the treated eye, with two neighboring points 
reaching significance (P=0.018, 0.038). When all the points across the treated 
and untreated eyes are combined, we again observe significant improvement in 
the ONL of the treated eyes as compared to the untreated (Figure 11). There 
were no inflammatory cells observed in either the AAV8.CBA.hCHM or the 
AAV8.EGFP-injected eyes. 
Transgenic human REP-1 is successfully expressed in ChmWT/null mouse 
retinas 
To confirm that AAV8.CBA.hCHM subretinal injection results in the 
localized expression of human REP-1 in treated ChmWT/null mice, we performed 
immunofluorescent labeling of retinal cryosections using a polyclonal human 
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specific REP-1 antibody produced in rabbits. In treated mouse eyes, labeling of 
human REP-1 was observed in the RPE and photoreceptor inner segments 
(Figure 9D), this recapitulates the REP-1 localization observed in 
immunofluorescent  labeled human retina sections (107). No human REP-1 
labeling was observed in the control retinas (Figure 9A), with robust EGFP 
expression in the remaining RPE and neural retina observed instead (Figure 9C). 
  
47 
DISCUSSION 
 
In this study we hypothesized that the introduction of functional human 
REP-1 to the RPE and photoreceptor cells of the retina would help ameliorate the 
retinal degeneration observed in a murine model of choroideremia. In order to 
test this, we produced an AAV8.CBA.hCHM vector which will express human 
REP-1 constitutively in transduced cells and injected CHM mice subretinally in 
one eye, while injecting an AAV8.EGFP expressing a reporter transgene as 
control in the contralateral eye.  
Treated mice were followed up at regular intervals via pupillometry and 
ophthalmoscopy, with a divergence is pupillary response observed between 
treated and control eyes in some mice at 32-39 weeks of age. In these mice the 
pupillary response in treated eye was more robust than that observed in control 
eyes, indicating improved retinal function in those eyes. While specific animals 
showed significant improvements in pupillary response, this was not observed 
across the entire treated population, with average pupillary response for all 
animals combined not showing a significant improvement in treated eyes 
(P=0.08). However, the remarkable improvement observed in some animals does 
suggest that treatment had a beneficial effect on pupillary response in those 
animals. 
Previous research involving the choroideremia mouse model used in this 
study indicated that there was significant outer nuclear layer loss at 
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approximately 8-16 months (16), therefore, we targeted this age range for a more 
invasive analysis of retinal histology. At 50 weeks of age the treated mice were 
sacrificed, and treated and control eyes were harvested and cryosectioned. 
Immunostaining of treated and control eyes for human REP-1 confirmed that we 
had induced the robust expression of REP-1 protein in treated retinas, with 
localization to the photoreceptor outer segments and RPE. This expression 
closely mirrored that observed in endogenous REP-1 localization in the human 
retina, and supports the conclusion that human exogenous REP-1 is functional 
and will localize correctly when expressed in retinal cells.  
The ONL of the retina is composed of the nuclei of photoreceptors cells. 
This means that the number of nuclei in the ONL directly corresponds to the 
number of rod and cone photoreceptors in the retina, with the thickness, in 
nuclei, of the ONL being considered a clear indicator of photoreceptor number 
and health. In order to quantitatively determine the health of treated retinas, as 
compared to controls, we measured the ONL thickness of treated and control 
retinas at set points along the retinas, and compared nuclei numbers between 
treated and controls. Our results indicated that at two conjoining points in the 
retinas there was a significant improvement in health in the treated retina. When 
these points were then combined to look at retinal thickness across all points, it 
was again demonstrated that the treated retinas were significant more healthy 
than the untreated retinas with regards to ONL thickness. While it could not be 
proven with this study, it is possible that the region of confluent improvement 
seen across the treated retinas may correspond to the subretinal injection site 
49 
where the AAV8.CBA.hCHM vector was delivered. However, this can’t be 
verified, as the injection sites could potentially vary among treated animals. 
In conclusion, we have demonstrated that an AAV8 vector expressing 
human REP-1 protein is capable of transducing the RPE and photoreceptor cells 
in a murine model of CHM, and reducing the observed degeneration in the 
treated retina as compared to control eyes. These results strongly support future 
attempts to move this potential therapeutic treatment to clinical trial. 
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FIGURES 
 
 
Figure 7: Ophthalmoscopy findings in AAV8.CBA.hCHM- and control 
(AAV8.EGFP-injected) retinas. 
Representative retinas from AAV8.CBA.hCHM-injected and AAV8.EGFP-injected 
ChmWT/null mice 1 and 50 weeks post-injection show diffuse pigmentary changes, 
similar to those observed prior to injection. EGFP is visible in the AAV8.EGFP-
injected retina (only) using a fluorescein filter (shown at the 1-week timepoint but 
continuing through termination of the study and visible even without using a lens 
to focus on the retina). There were greater areas of depigmentation in 
AAV8.EGFP-injected retinas 50 weeks after injection, although the appearance 
of AAV8.CBA.hCHM-injected retinas was similar to that observed soon after 
injection. 
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Figure 8. Pupillometry analysis of AAV8.CBA.hCHM treat CHM mice. 
Representative pupillary light reflex traces 49 weeks after injection of the right 
eye with AAV8.CBA.hCHM and the left eye (control) with AAV8.EGFP. Brisk 
pupillary constriction is observed after the right eye (but not the left eye) is 
stimulated. Left and right pupils are indicated by blue and red traces, 
respectively, as a function of time after each flash of light (vertical dotted lines). 
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Figure 9. Histological and immunofluorescent analysis of retinas from 
AAV8.CBA.hCHM treated CHMWT/null mice. 
REP-1 immunofluorescent and H&E staining collage of control (A–C) and treated 
(D–E) CHM mouse retinas. (A) There is no detectable immunofluorescence 
specific to human REP-1 in the AAV8.EGFP-injected retina. (B) H&E staining 
reveal loss of ONL. (C) GFP is present in the treated portion of the retina at high 
levels in the RPE and remaining neural retina. By contrast, REP-1 protein is 
immunofluorescently detectable in RPE and photoreceptor inner segments in 
AAVCHM-treated retinas (D). (E) H&E staining shows preservation of the ONL. 
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Representative AAV8.CBA.hCHM-treated retina is shown at approximately 50 
weeks of age. 
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Figure 10. Spidergram of retinal outer nuclear layer (ONL) thickness. 
Graph depicting average ONL layer thickness for untreated and treated eyes 
across six points in the retina. Two neighboring points show significant 
improvement in the treated eye (p=0.018 and 0.038). Analyzed retinas harvested 
from animals at approximately 50 weeks of age. 
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Figure 11. Combined ONL across all measured points. 
Comparison of untreated and treated ONL thickness using an average of all 
measured points in the retinas. The treated retina shows a significant 
improvement in ONL thickness compared to the untreated retina (p=0.049). Error 
bars represent IQR. Analyzed retinas harvested from animals at approximately 
50 weeks of age. 
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CONCLUSION AND FUTURE DIRECTIONS 
 
CONCLUSION 
 
Although the molecular basis of choroideremia was first characterized and 
the gene cloned more than 23 years ago (108-109), progress in demonstrating 
proof-of-concept of gene augmentation therapy has only recently emerged for 
this disease. This is for two main reasons: 1) it has been difficult to generate an 
accurate animal model of the disease phenotype since lack of REP-1 is lethal in 
the mouse (110). This has made it difficult to unequivocally identify the primary 
cell type initiating the disease and also to test therapies; and 2) it was not until 
recently that vectors capable of delivering genes safely and efficiently to the 
appropriate retinal target cells were identified. There is now a large body of data 
relating to the safety and efficacy after subretinal injection of rAAV serotype 2 
(AAV2) generated in human clinical trials for Leber congenital amaurosis due to 
RPE65 mutations (74-76, 80, 92-94, 111-113). Soon there will be additional data 
available on the safety profile of AAV2 used to treat choroidal neovascularization 
in wet age-related macular degeneration and choroideremia 
(http:/clinicaltrials.gov). 
It was sensible to move forward with gene therapy for choroideremia using 
AAV2, as has been done by MacLaren, During, Seabra and colleagues, as this 
vector serotype can target RPE and photoreceptors safely and efficiently and in a 
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stable fashion (68). Preliminary results from their Phase 1 clinical trial show a 
high degree of safety and evidence of efficacy in two of six subjects. In an effort 
to develop a vector which could be used to target RPE and photoreceptor cells 
even more efficiently (and thus potentially at a lower dose) than AAV2, we 
explored applications of rAAV8 to choroideremia. AAV8 is known to target a 
diverse set of retinal cells, including RPE cells and photoreceptors, safely in 
mice, dogs and non-human primates (70, 101). AAV8-mediated transgene 
expression reaches maximal levels much sooner than does AAV2-mediated 
expression. Furthermore, AAV8 can be used at ten times less than the dose of 
AAV2 to achieve equivalent expression in the same set of cells (70, 89, 101). 
AAV8 has been used successfully in a gene augmentation therapy approach in 
animal models of achromatopsia, LCA, autosomal recessive retinitis pigmentosa, 
and retinoschisis (114-117). It has also been applied to humans with hemophilia, 
without any adverse safety issues (118). Similar to the way that use of AAV2 in 
LCA-RPE65 has expedited development of AAV2 for other blinding human 
conditions, use of AAV8 in a human clinical trial for choroideremia could not only 
result in robust safety and efficacy data but could also serve as a stepping stone 
for using AAV8 in other, less common, human retinal degenerative conditions. 
Recently, Tolmachova et al described safety and efficacy of subretinal 
delivery of an AAV2.CBA.CHM vector after subretinal injection in ChmWT/null mice 
(98). Their data demonstrated transduction of the RPE and improvement in 
electroretinogram (ERG) a- and b-waves in comparison to sham-injected eyes. 
The ERG response reflects improvement of function in the neural retina. In the 
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present study, we have evaluated the effects of a vector, AAV8, which 
transduces photoreceptors more efficiently than AAV2. This vector, like AAV2, 
also transduces RPE cells. We demonstrated, through use of pupillometry, that 
signals originating in the AAV8.CBA.hCHM-injected ChmWT/null retinas are relayed 
to the brain. We also demonstrated that AAV8-mediated delivery of the wildtype 
human CHM cDNA resulted in efficient production of REP-1 in CHO cells and 
COS7 cells. Although CHO and COS7 cells have endogenous (hamster and 
monkey, respectively) REP-1, we were able to take advantage of a human-REP-
1-specific antibody to demonstrate expression. We then proved that this 
exogenous REP-1 functions properly, with regards to the prenylation of Rab 
proteins, both in COS7 cells transduced with AAV8.CBA.hCHM and CHM patient 
derived fibroblasts transduced with AAV2.CBA.hCHM produced using the same 
proviral plasmid. The next step was to evaluate safety and efficacy in an animal 
model of choroideremia, the ChmWT/null mouse. For this, we carried out subretinal 
injections of AAV8.CBA.hCHM in one eye and injected the contralateral eye with 
AAV8.EGFP as control. The animals were followed serially over the next half 
year for safety and efficacy. There was no evidence at any timepoint of 
inflammation due to exposure to AAV8 or to the human CHM transgene. Results 
showed robust preservation of pupillary response and retinal morphology in the 
eyes treated with AAV8.CBA.hCHM but not in the control eyes.  Rescue was 
confirmed histologically, with the photoreceptor and RPE layers of experimental 
eyes overall remaining more intact than those of the control eyes. Furthermore, 
the REP-1 protein could be detected in the experimental but not control eyes. 
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One challenge with interpretation of the data is that we cannot exclude the 
possibility that exposure to EGFP protein resulted in toxicity in the control eyes. 
Due to the limited number of animals, we were not able to assess this possibility. 
We have carried out numerous studies using EGFP as a control transgene and 
have only seen evidence of a cell-mediated immune response directed at EGFP 
in one experiment (101). That experiment involved non-human primates, not 
mice. Since we did not have enough animals to add an additional cohort of 
uninjected (or sham-injected) control eyes, we cannot rule out the potential of 
EGFP-mediated toxicity. Nevertheless, we can still conclude that exposure to 
AAV8 and the CHM transgene was not toxic and delivery of AAV8.CBA.hCHM 
resulted in longterm rescue of retinal-cortical function in ChmWT/null mice without 
any apparent local or systemic toxicity. The data reported here is the first step in 
developing proof-of-concept of AAV8-mediated retinal gene therapy for 
choroideremia. 
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FUTURE DIRECTIONS 
 
Improved In Vitro Models 
 
The cells of the neural retina are highly specialized, with little resemblance 
to commonly used immortalized cell lines. With the exception of RPE cells, 
attempts to isolate or produce immortalized cell lines from retinal tissues have 
met with very limited success, with the generated line often retaining very few 
unique characteristics of the cell types they were originally derived from. Working 
with primary tissue cultures harvested from animals and humans can correct 
some of these problems, but, result in new difficulties including cells only being 
viable for a short time and the need to obtain fresh tissue regularly, a real 
challenge if you are working with human tissue. These limitations are 
complicated further when the subject of research is a genetic disease, as ideally 
you would wish to conduct investigations of potential treatments in cells derived 
from an affected individual. In the case of fibroblasts and lymphoblasts this is a 
possibility, but, to work with retinal tissue, for example, would require harvest 
within hours of death of ocular tissue from a molecular characterized 
choroidermia patient. So far, such tissue has not been available. If it were,the 
harvest could potentially yield a primary RPE cell model of choroideremia, but not 
a line of neuronal cells. Therefore, means by which to produce retinal cells, 
particularly RPE and photoreceptors, with known CHM mutations would provide 
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researchers with a powerful platform from which to study the molecular 
mechanisms of the disease and test potential therapeutics. Recent advances in 
the field of induced pluripotent stem (iPS) cell derived tissues may offer the 
answer to this need. It has become possible to reliably produce iPS cells from 
patient peripheral blood mononuclear cells (PBMCs) (119) and fibroblasts (120), 
and derivation protocols now exist to produce iPS-RPE cells whose function and 
appearance very closely match that of primary RPE cells (121-122). In theory, 
iPS cells derived from a CHM affected individual can be differentiated into these 
iPS-RPE cells, providing a reliable supply of affected RPE cells for studies of 
disease mechanisms and the effects of exogenous REP-1 introduction on cell 
function. In particular, photoreceptor outer segment phagocytosis assays are a 
commonly used method to analyze RPE function, and phagocytosis has been 
shown to be perturbed in immortalized RPE cells with REP-1 siRNA KD (20). 
REP-1 deficient iPS-RPE cells would allow us to verify this abnormality in patient 
cells as well as ascertain whether potential treatments are capable of 
ameliorating the dysfunction.  
The production of functional photoreceptors from iPS cells is a challenging 
prospect due to the increased complexity of photoreceptors and their high 
dependence upon neighboring tissues for proper function and development. 
However, advances are currently being made in this area. We and others are 
now able to generate neural retina precursor cells reliably from iPS cells and 
these cells can have features of differentiating photoreceptors. In fact, the cells 
congregate into pseudo-eye cups containing multiple retinal layers (123). It is 
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likely that steps will be identified in the near future allowing these eye cups to 
fully recapitulate the development/function of neural retinal cells in vivo,  This will 
allow studies of disease mechanism and will expedite the development of 
therapeutic strategies, including gene therapy.  
Improved Animal Models 
 
One of the greatest challenges faced by those attempting translational 
research of choroideremia is the lack of animal models which faithfully reproduce 
the human disease phenotype. This is compounded by the fact that the (one) 
murine model of the disease exhibits a slow degeneration (detectable after 50 
weeks). This poses practical problems for a laboratory as the timeline of 
experiments is long. 
Recently generated models have attempted to improve upon this original 
system by instead producing mouse lines with tissue specific Cre expression in 
either the RPE, photoreceptors, or both tissues concurrently. By crossing this 
tissue specific Cre expressing strain with the already existing floxed-Chm strain 
(Chmflox), it is possible to produce a mouse strain which will spontaneously KO 
the Chm gene in only the RPE and photoreceptors (19). Some of the immediate 
benefits of this method include a much easier breeding strategy for the disease 
model and a disease phenotype which should theoretically be more true to that 
observed in affected human males. This is due to the new murine model 
disrupting REP-1 expression in all RPE and photoreceptor cells, rather than 
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depending upon lyonization in the retinas of ChmWT/null heterozygous females to 
achieve a mosaic KO. Instead, this method should result in a complete KO of 
Chm in both the RPE and the photoreceptors. Unfortunately, while these 
conditional KO models did allow for a better understanding of CHM tissue 
pathology, they did not show retinal degeneration which was significantly more 
severe than that observed in the Chmnull/WT model (16, 19). Therefore, the 
generation of animal models of choroideremia which both exhibit a disease 
phenotype more similar to that seen in affected humans and experience a faster 
disease onset to allow for shorter studies is highly desirable. Ideally these 
models would include both a small animal model for easy studies with high 
numbers of treated animals, and a large animal model for therapy treatment in a 
system which more closely resembles humans. 
Murine disease models are a gold standard for potential therapy testing 
due to their quick maturation, large litter numbers, relatively low resource 
requirements, ease of handling, and vast pre-existing research community 
resources. However, generation of a murine choroideremia model has been 
complicated due to KO of Chm being embryonic lethal in mice. As previously 
mentioned, methods have been found to circumvent this, but, degeneration in the 
mice is still dissimilar to that observed in humans, and, most importantly, occurs 
over a timespan that is substantially longer than ideal. Therefore, the generation 
of a murine model with a quicker disease onset and progression would be a 
powerful tool in the research of choroideremia therapies. 
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Seabra’s work with the newest conditional tissue-specific Cre expressing 
Chmflox model suggests that even mostly complete loss of Rep-1 expression in 
the RPE and photoreceptors is not sufficient to produce a disease model with 
efficient disease pathology. Therefore, approaches by which this degeneration 
can be accelerated, either by further disrupting the Rab prenylation pathway, or 
by otherwise enhancing the degeneration in a Chm mutation dependent fashion, 
are a promising area of research. 
As previously described, Rep-1 is involved in the activation-by-prenylation 
of Rab proteins. These proteins associate with the cell membrane and are vital 
for intracellular trafficking. In humans, it is thought that the lack of functional 
REP-1 is mitigated by the presence of REP-2, a protein which shares a 71% 
homology with REP-1. REP-2 has been shown to also be capable of presenting 
Rab proteins for prenylation, although at a lesser efficiency than REP-1 for some 
Rab proteins (12-14). Little work has so far been done examining the murine 
homologue of REP-2, Rep-2, but, it has been demonstrated via in situ 
hybridization that Rep-2 mRNA is present in the same area of the murine retina 
as is the mRNA of Rep-1 (15). This strongly suggests that Rep-2 protein is also 
present in those tissues and is likely assisting in the prenylation of Rab proteins. 
This makes the Rep-2 gene an excellent candidate for KD or KO to further 
exacerbate the decrease in the Rab prenylation caused by Rep-1 KO. It has 
already been observed in a zebrafish model of CHM, which lacks the Rep-2 
gene, that the complete loss of Rab prenylation is disastrous for proper cellular 
function, quickly resulting in the death of fertilized embryos (23). Presumably, 
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eliminating both Rep-1 and Rep-2 in the murine eye could have a similar effect, 
resulting in an abrupt degeneration of the RPE and photoreceptors which should 
still be mostly treatable with the reinstatement of Rep-1 expression via gene 
therapy. Potential complications of this model include that, without any Rab 
prenylation, degeneration will be so fast that it will be difficult to treat mice before 
the complete loss of the target cell layers, and the possibility that the 
reinstatement of Rep-1 expression will not be enough to compensate for the lack 
of Rep-2. The former complication would be a difficult one to ameliorate, and 
could either require in utero treatment of the model to transduce still healthy cells 
or the use of a less stringent means of Rep-2 KD, such as siRNA, so as not to 
entirely eliminate its expression. 
Another potential method to further reduce the prenylation of Rab proteins 
in a retinal tissue-specific Chmflox model would be to cross it with mice with the 
gunmetal (gm) mutation. Gm mice possess a G to A substitution mutation in a 
splice acceptor site at the start of exon 1 in the Rab geranylgeranyl transferase 
gene (124). This mutation results in exon 1 being spliced out in most mature 
mRNAs, causing the loss of the gene’s normal start codon. The resulting mRNA 
is unlikely to be translated. To a much lesser degree, a cryptic splice acceptor 
and donor site allows for an mRNA retaining exon 1 to be produced in gm mice, 
which enables the production of geranylgeranyl transferase at approximately a 
fourth the level seen in wt mice. Geranylgeranyl transferase interacts with REP-1 
and Rab proteins to effect the addition of geranylgeranyl prenyl groups to the 
Rab proteins. In the gm mouse the reduction in geranylgeranyl transferase 
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corresponds with a significant drop in the levels of prenylated Rab proteins, 
similar to that observed in CHM patients (124). These mice exhibit partial 
cutaneous albinism, prolonged bleeding, platelet abnormalities, and 
thrombocytopenia, but, no obvious visual defects. By crossing tissue-specific Cre 
expressing Chmflox mice with the gm model, it may be possible to generate mice 
with a greater reduction in Rab prenylation in the RPE and photoreceptors than is 
observed in either model alone. This could result in a model which will exhibit 
more severe degeneration in the retina, but, still be amenable to rescue with the 
addition of a REP-1 transgene. 
While small animal models are excellent for fast, inexpensive proof of 
concept experiments, they often falter at being direct translations of the disease 
phenotype observed in humans due to large differences in genetics and 
physiology. Attempts to produce a Chmnull/Y mouse model is an excellent 
example of this, as it was discovered that the KO of Chm was embryonic lethal in 
mice (24), whereas the only observed disease phenotype in humans is retinal 
dystrophy. Physiological differences also play a significant role, as mice and 
many other small animal models do not possess organs that closely mimic those 
seen in humans. In the case of the eye, mice do not possess a macula, a cone 
dense central region seen only in primates, and overall have very low levels of 
cones, approximately 1%, compared to humans, ~5% (125-126). Mice are 
dichromats, with two types of cones that express two different light sensitive 
opsins, for medium and ultraviolet wavelengths (127), humans, on the other 
hand, are trichromats, with 3 different types of cone opsins that are sensitive at 
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short, medium, and long wavelengths (128-129). The morphology of murine and 
primate eyes is also vastly different, with the lens in murine eyes taking up much 
of the interior of the eye, greatly restricting the size of the vitreous chamber. In 
comparison, the primate lens composes much less of the interior of the eye, 
resulting in a far larger vitreous chamber relative to the size of the eye. This 
results in treatments that might target the vitreous chamber, such as intra-vitrial 
injections, having drastically different mechanics depending upon whether you 
are testing them in murine and other small rodent models, or in large animal 
models, as dilution factors in the vitreous are vastly different in rodents versus 
large animal models. These differences mean that while murine models might be 
useful and efficient for translational work, it is important to correlate results 
between small and large animal models. 
Swine are considered an ideal large animal model when pursuing 
translational research for human diseases due to their similar genetics, 
physiology, and anatomy (130). In fact, swine organs so closely resemble those 
of humans that swine are now being engineered for xenotransplantation (131-
132). In the eye, swine lack a macula, as do all non-primates, but, they do 
possess a cone-rich horizontal temporal to nasal retinal streak across the retina, 
as well as a rod-rich retinal periphery (133), a configuration analogous to a 
macula. Remarkably, swine retinas are richer in cone photoreceptors than 
human retinas, with levels of approximately 20-30% (134). Like mice, swine are 
dichromats, however, they possess short- and medium-wavelength cones, both 
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of which are shared with trichromat humans, while mice possess medium- and 
ultraviolet-wavelength cones, only one of which is shared with humans (133). 
Engineering swine disease models is a process that has undergone rapid 
progress over the last two decades. While initially only crude random transgene 
addition was possible via pronuclear injection of zygotes (135), methods of 
targeted transgene introduction or gene modification have become possible 
through the modification of swine somatic cell genomes via homologous 
recombination (136), zinc finger nucleases (137), transposases (138), 
CRISPR/Cas9 (139), and other genome editing methods, followed by somatic 
cell nuclear transfer (SCNT) of desired genetic modifications into porcine 
zygotes. At this time a number of swine models for human disease have been 
produced, including for retinitis pigmentosa (140), autosomal dominant Stargardt-
like macular dystrophy type 3 (141), hypertriglyceridemia (142), and cystic 
fibrosis (143-144). The cystic fibrosis model is of particular interest because it 
highlights the complications which can occur when you attempt to model human 
diseases in small animal models. Murine models of cystic fibrosis do not exhibit 
all the classic symptoms of cystic fibrosis (145) and have been of only moderate 
use in modeling disease progression. In comparison, the swine models of cystic 
fibrosis so far produced have displayed disease phenotypes which very closely 
resemble those observed in humans and have allowed the discovery of hereto 
unknown disease mechanisms (146). While it is not assured, the much greater 
similarities in development between swine and humans as compared to mice and 
humans supports the idea that generation of a CHM model in swine may result in 
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a viable large animal model which presents a disease phenotype more in step 
with what it observed in affected humans. 
There a number of potential complications which could arise when attempt 
to produce a swine model of choroideremia. The most obvious of these is that 
the KO of CHM will prove to be embryonic lethal in swine as well as mice. This 
outcome would not be recoverable, and research would need to progress in other 
directions. However, chances of this occurring are hopefully low, due to swine 
having much more in common with humans than mice. The next danger is that 
while the CHMnull/Y model production will be successful and display retinal 
degeneration, it will be a very slow degeneration, as seen in the mice. Given that 
miniature pigs, which are typically used as the background for swine models, can 
live 12-28 years (147), it is possible that a swine model of CHM could take 
upwards of 5 years to display a disease phenotype, a time span that would not 
be ideal for translational studies but which would more accurately model the 
human condition, This problem could be approached using methods similar to 
those suggested above to address the slow degeneration in murine models, 
either by targeting expression of REP-2 for KD, or by attempting to hinder 
another part of the Rab prenylation pathway so as to exacerbate the 
degeneration. 
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